Compile Data Set for Download or QSAR
Report error Found 31 Enz. Inhib. hit(s) with all data for entry = 10031
TargetGalectin-3(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM509535(US11072626, Example 22)
Affinity DataIC50: 43nMAssay Description:ASSAY BUFFER Composition: 25 mM HEPES, 100 mM NaCl, 0.005% Tween 20, 0.05% BSA prepared in sterile water (all reagents from Sigma). PROTOCOL: The Gal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM509530(US11072626, Example 2 | 3: (2R,3R,4S,5R,6R)-6-((R)...)
Affinity DataIC50: 46nMAssay Description:ASSAY BUFFER Composition: 25 mM HEPES, 100 mM NaCl, 0.005% Tween 20, 0.05% BSA prepared in sterile water (all reagents from Sigma). PROTOCOL: The Gal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM509541(US11072626, Example 28)
Affinity DataIC50: 48nMAssay Description:ASSAY BUFFER Composition: 25 mM HEPES, 100 mM NaCl, 0.005% Tween 20, 0.05% BSA prepared in sterile water (all reagents from Sigma). PROTOCOL: The Gal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM509546(US11072626, Example 33)
Affinity DataIC50: 60nMAssay Description:ASSAY BUFFER Composition: 25 mM HEPES, 100 mM NaCl, 0.005% Tween 20, 0.05% BSA prepared in sterile water (all reagents from Sigma). PROTOCOL: The Gal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM509536(US11072626, Example 23)
Affinity DataIC50: 60nMAssay Description:ASSAY BUFFER Composition: 25 mM HEPES, 100 mM NaCl, 0.005% Tween 20, 0.05% BSA prepared in sterile water (all reagents from Sigma). PROTOCOL: The Gal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM509556(US11072626, Example 55)
Affinity DataIC50: 70nMAssay Description:ASSAY BUFFER Composition: 25 mM HEPES, 100 mM NaCl, 0.005% Tween 20, 0.05% BSA prepared in sterile water (all reagents from Sigma). PROTOCOL: The Gal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM509540(US11072626, Example 27)
Affinity DataIC50: 70nMAssay Description:ASSAY BUFFER Composition: 25 mM HEPES, 100 mM NaCl, 0.005% Tween 20, 0.05% BSA prepared in sterile water (all reagents from Sigma). PROTOCOL: The Gal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM509542(US11072626, Example 29)
Affinity DataIC50: 72nMAssay Description:ASSAY BUFFER Composition: 25 mM HEPES, 100 mM NaCl, 0.005% Tween 20, 0.05% BSA prepared in sterile water (all reagents from Sigma). PROTOCOL: The Gal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM509538(US11072626, Example 25)
Affinity DataIC50: 76nMAssay Description:ASSAY BUFFER Composition: 25 mM HEPES, 100 mM NaCl, 0.005% Tween 20, 0.05% BSA prepared in sterile water (all reagents from Sigma). PROTOCOL: The Gal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM509539(US11072626, Example 26)
Affinity DataIC50: 86nMAssay Description:ASSAY BUFFER Composition: 25 mM HEPES, 100 mM NaCl, 0.005% Tween 20, 0.05% BSA prepared in sterile water (all reagents from Sigma). PROTOCOL: The Gal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM509544(US11072626, Example 31)
Affinity DataIC50: 90nMAssay Description:ASSAY BUFFER Composition: 25 mM HEPES, 100 mM NaCl, 0.005% Tween 20, 0.05% BSA prepared in sterile water (all reagents from Sigma). PROTOCOL: The Gal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM509537(US11072626, Example 24)
Affinity DataIC50: 150nMAssay Description:ASSAY BUFFER Composition: 25 mM HEPES, 100 mM NaCl, 0.005% Tween 20, 0.05% BSA prepared in sterile water (all reagents from Sigma). PROTOCOL: The Gal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM509533(US11072626, Example 5)
Affinity DataIC50: 195nMAssay Description:ASSAY BUFFER Composition: 25 mM HEPES, 100 mM NaCl, 0.005% Tween 20, 0.05% BSA prepared in sterile water (all reagents from Sigma). PROTOCOL: The Gal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM509531(US11072626, Example 3)
Affinity DataIC50: 200nMAssay Description:ASSAY BUFFER Composition: 25 mM HEPES, 100 mM NaCl, 0.005% Tween 20, 0.05% BSA prepared in sterile water (all reagents from Sigma). PROTOCOL: The Gal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM509532(US11072626, Example 4)
Affinity DataIC50: 224nMAssay Description:ASSAY BUFFER Composition: 25 mM HEPES, 100 mM NaCl, 0.005% Tween 20, 0.05% BSA prepared in sterile water (all reagents from Sigma). PROTOCOL: The Gal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM509534(US11072626, Example 21)
Affinity DataIC50: 225nMAssay Description:ASSAY BUFFER Composition: 25 mM HEPES, 100 mM NaCl, 0.005% Tween 20, 0.05% BSA prepared in sterile water (all reagents from Sigma). PROTOCOL: The Gal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM509555(US11072626, Example 54)
Affinity DataIC50: 230nMAssay Description:ASSAY BUFFER Composition: 25 mM HEPES, 100 mM NaCl, 0.005% Tween 20, 0.05% BSA prepared in sterile water (all reagents from Sigma). PROTOCOL: The Gal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM509553(US11072626, Example 52)
Affinity DataIC50: 250nMAssay Description:ASSAY BUFFER Composition: 25 mM HEPES, 100 mM NaCl, 0.005% Tween 20, 0.05% BSA prepared in sterile water (all reagents from Sigma). PROTOCOL: The Gal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM509558(US11072626, Example 57)
Affinity DataIC50: 310nMAssay Description:ASSAY BUFFER Composition: 25 mM HEPES, 100 mM NaCl, 0.005% Tween 20, 0.05% BSA prepared in sterile water (all reagents from Sigma). PROTOCOL: The Gal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM509551(US11072626, Example 50)
Affinity DataIC50: 620nMAssay Description:ASSAY BUFFER Composition: 25 mM HEPES, 100 mM NaCl, 0.005% Tween 20, 0.05% BSA prepared in sterile water (all reagents from Sigma). PROTOCOL: The Gal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM509547(US11072626, Example 34)
Affinity DataIC50: 660nMAssay Description:ASSAY BUFFER Composition: 25 mM HEPES, 100 mM NaCl, 0.005% Tween 20, 0.05% BSA prepared in sterile water (all reagents from Sigma). PROTOCOL: The Gal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM509545(US11072626, Example 32)
Affinity DataIC50: 700nMAssay Description:ASSAY BUFFER Composition: 25 mM HEPES, 100 mM NaCl, 0.005% Tween 20, 0.05% BSA prepared in sterile water (all reagents from Sigma). PROTOCOL: The Gal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM509549(US11072626, Example 48)
Affinity DataIC50: 740nMAssay Description:ASSAY BUFFER Composition: 25 mM HEPES, 100 mM NaCl, 0.005% Tween 20, 0.05% BSA prepared in sterile water (all reagents from Sigma). PROTOCOL: The Gal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM509543(US11072626, Example 30)
Affinity DataIC50: 800nMAssay Description:ASSAY BUFFER Composition: 25 mM HEPES, 100 mM NaCl, 0.005% Tween 20, 0.05% BSA prepared in sterile water (all reagents from Sigma). PROTOCOL: The Gal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM509559(US11072626, Example 58)
Affinity DataIC50: 840nMAssay Description:ASSAY BUFFER Composition: 25 mM HEPES, 100 mM NaCl, 0.005% Tween 20, 0.05% BSA prepared in sterile water (all reagents from Sigma). PROTOCOL: The Gal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM509550(US11072626, Example 49)
Affinity DataIC50: 1.34E+3nMAssay Description:ASSAY BUFFER Composition: 25 mM HEPES, 100 mM NaCl, 0.005% Tween 20, 0.05% BSA prepared in sterile water (all reagents from Sigma). PROTOCOL: The Gal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM509548(US11072626, Example 47)
Affinity DataIC50: 1.53E+3nMAssay Description:ASSAY BUFFER Composition: 25 mM HEPES, 100 mM NaCl, 0.005% Tween 20, 0.05% BSA prepared in sterile water (all reagents from Sigma). PROTOCOL: The Gal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM509552(US11072626, Example 51)
Affinity DataIC50: 1.61E+3nMAssay Description:ASSAY BUFFER Composition: 25 mM HEPES, 100 mM NaCl, 0.005% Tween 20, 0.05% BSA prepared in sterile water (all reagents from Sigma). PROTOCOL: The Gal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM509554(US11072626, Example 53)
Affinity DataIC50: 1.75E+3nMAssay Description:ASSAY BUFFER Composition: 25 mM HEPES, 100 mM NaCl, 0.005% Tween 20, 0.05% BSA prepared in sterile water (all reagents from Sigma). PROTOCOL: The Gal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM509560(US11072626, Example 59)
Affinity DataIC50: 5.55E+3nMAssay Description:ASSAY BUFFER Composition: 25 mM HEPES, 100 mM NaCl, 0.005% Tween 20, 0.05% BSA prepared in sterile water (all reagents from Sigma). PROTOCOL: The Gal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent

TargetGalectin-3(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM509557(US11072626, Example 56)
Affinity DataIC50: 7.43E+3nMAssay Description:ASSAY BUFFER Composition: 25 mM HEPES, 100 mM NaCl, 0.005% Tween 20, 0.05% BSA prepared in sterile water (all reagents from Sigma). PROTOCOL: The Gal...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
Go to US Patent